© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Axe Compute Inc. (AGPU) stock declined over -0.96%, trading at $8.27 on NASDAQ, down from the previous close of $8.35. The stock opened at $8.62, fluctuating between $8.05 and $8.63 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | 8.63 | 8.65 | 8.05 | 8.27 | 235.87K |
| Aug 13, 2026 | 8.08 | 8.44 | 8.01 | 8.35 | 106.06K |
| Aug 12, 2026 | 8.18 | 8.51 | 8.00 | 8.04 | 109.52K |
| Aug 11, 2026 | 8.52 | 8.52 | 7.73 | 8.01 | 143.69K |
| Aug 10, 2026 | 8.50 | 8.69 | 8.25 | 8.41 | 194.57K |
| Aug 07, 2026 | 8.62 | 8.78 | 8.30 | 8.40 | 138.72K |
| Aug 06, 2026 | 9.19 | 9.65 | 8.31 | 8.38 | 330.97K |
| Aug 05, 2026 | 9.12 | 9.42 | 8.77 | 9.19 | 266.7K |
| Aug 04, 2026 | 8.47 | 9.22 | 8.46 | 9.01 | 293.62K |
| Aug 03, 2026 | 8.47 | 9.29 | 8.23 | 8.44 | 316.37K |
| Jul 31, 2026 | 8.45 | 8.50 | 7.80 | 8.38 | 201.99K |
| Jul 30, 2026 | 7.11 | 8.62 | 7.11 | 8.50 | 501.92K |
| Jul 29, 2026 | 7.09 | 7.45 | 6.90 | 7.02 | 282.68K |
| Jul 28, 2026 | 7.21 | 7.74 | 7.12 | 7.33 | 389.93K |
| Jul 27, 2026 | 7.87 | 8.24 | 6.63 | 7.21 | 3.41M |
| Jul 24, 2026 | 7.40 | 7.49 | 6.80 | 6.85 | 287.87K |
| Jul 23, 2026 | 7.12 | 7.77 | 6.85 | 7.36 | 739.97K |
| Jul 22, 2026 | 9.47 | 9.48 | 6.61 | 7.11 | 3.04M |
| Jul 21, 2026 | 8.60 | 10.00 | 8.60 | 9.54 | 894.49K |
| Jul 20, 2026 | 6.99 | 9.00 | 6.83 | 8.71 | 809.97K |
Headquartered in Pittsburgh, Pennsylvania, Axe Compute Inc., established in 2002 and formerly known as Predictive Oncology Inc. until its December 2025 renaming, is an enterprise that leverages profound scientific insights and artificial intelligence (AI) to advance the discovery and development of cancer treatments. The company's operations are divided into two distinct segments. Its Pittsburgh division offers AI-driven services, utilizing an exclusive biobank containing over 150,000 tumor samples, and engineers specialized 3D cell culture models vital for drug advancement. Meanwhile, the Eagan division produces the FDA-approved STREAMWAY System and related products, which facilitate automated medical fluid waste management and direct patient-to-drain fluid disposal. Additionally, Axe Compute maintains a strategic partnership with Every Cure to identify and prioritize existing pharmaceuticals for repurposing.
| Employees | 14 |
| Beta | 3.47 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | N/A |
| Fiscal Year Ends | N/A |
| Sector | Technology |
| Industry | Software - Infrastructure |